258 related articles for article (PubMed ID: 25424855)
1. HER2 as a therapeutic target in head and neck squamous cell carcinoma.
Pollock NI; Grandis JR
Clin Cancer Res; 2015 Feb; 21(3):526-33. PubMed ID: 25424855
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs for head and neck cancer.
Wen Y; Grandis JR
Expert Opin Emerg Drugs; 2015 Jun; 20(2):313-29. PubMed ID: 25826749
[TBL] [Abstract][Full Text] [Related]
3. Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives.
Ausoni S; Boscolo-Rizzo P; Singh B; Da Mosto MC; Spinato G; Tirelli G; Spinato R; Azzarello G
Cancer Metastasis Rev; 2016 Sep; 35(3):413-26. PubMed ID: 27194534
[TBL] [Abstract][Full Text] [Related]
4. Angiogenin-mediated ribosomal RNA transcription as a molecular target for treatment of head and neck squamous cell carcinoma.
Chen L; Hu GF
Oral Oncol; 2010 Sep; 46(9):648-53. PubMed ID: 20656548
[TBL] [Abstract][Full Text] [Related]
5. Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data.
Giefing M; Wierzbicka M; Szyfter K; Brenner JC; Braakhuis BJ; Brakenhoff RH; Bradford CR; Sorensen JA; Rinaldo A; Rodrigo JP; Takes RP; Ferlito A
Eur J Cancer; 2016 Mar; 55():147-57. PubMed ID: 26851381
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs to treat squamous cell carcinomas of the head and neck.
Fung C; Grandis JR
Expert Opin Emerg Drugs; 2010 Sep; 15(3):355-73. PubMed ID: 20557270
[TBL] [Abstract][Full Text] [Related]
7. EphB4: A promising target for upper aerodigestive malignancies.
Salgia R; Kulkarni P; Gill PS
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):128-137. PubMed ID: 29369779
[TBL] [Abstract][Full Text] [Related]
8. Genomic sequencing and precision medicine in head and neck cancers.
Hoesli RC; Ludwig ML; Michmerhuizen NL; Rosko AJ; Spector ME; Brenner JC; Birkeland AC
Eur J Surg Oncol; 2017 May; 43(5):884-892. PubMed ID: 28034498
[TBL] [Abstract][Full Text] [Related]
9. The role of ferroptosis in radiotherapy and combination therapy for head and neck squamous cell carcinoma (Review).
Feng Y; Li X; Yang B; Li M; Du Y; Wang J; Liu S; Gong L; Li L; Gao L
Oncol Rep; 2024 Jun; 51(6):. PubMed ID: 38639185
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine Factors and Head and Neck Squamous Cell Carcinoma: An Affair to Remember.
Solomon I; Voiculescu VM; Caruntu C; Lupu M; Popa A; Ilie MA; Albulescu R; Caruntu A; Tanase C; Constantin C; Neagu M; Boda D
Dis Markers; 2018; 2018():9787831. PubMed ID: 29854027
[TBL] [Abstract][Full Text] [Related]
11. Modulators of Redox Metabolism in Head and Neck Cancer.
Chen X; Mims J; Huang X; Singh N; Motea E; Planchon SM; Beg M; Tsang AW; Porosnicu M; Kemp ML; Boothman DA; Furdui CM
Antioxid Redox Signal; 2018 Dec; 29(16):1660-1690. PubMed ID: 29113454
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention of Head and Neck Cancers: Does It Have Only One Face?
Siemianowicz K; Likus W; Dorecka M; Wilk R; Dziubdziela W; Markowski J
Biomed Res Int; 2018; 2018():9051854. PubMed ID: 30356371
[TBL] [Abstract][Full Text] [Related]
13. Progress of molecular targeted therapy for head and neck cancer in clinical aspects.
Nakano K
Mol Biomed; 2021 May; 2(1):15. PubMed ID: 35006440
[TBL] [Abstract][Full Text] [Related]
14. Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors.
Sacco AG; Worden FP
Onco Targets Ther; 2016; 9():1927-43. PubMed ID: 27110122
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive genomic characterization of head and neck squamous cell carcinomas.
Cancer Genome Atlas Network
Nature; 2015 Jan; 517(7536):576-82. PubMed ID: 25631445
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic insights from genomic studies of head and neck squamous cell carcinomas.
Hammerman PS; Hayes DN; Grandis JR
Cancer Discov; 2015 Mar; 5(3):239-44. PubMed ID: 25643909
[TBL] [Abstract][Full Text] [Related]
17. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.
Galloway TJ; Wirth LJ; Colevas AD; Gilbert J; Bauman JE; Saba NF; Raben D; Mehra R; Ma AW; Atoyan R; Wang J; Burtness B; Jimeno A
Clin Cancer Res; 2015 Apr; 21(7):1566-73. PubMed ID: 25573383
[TBL] [Abstract][Full Text] [Related]
18. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
Trials; 2014 Nov; 15():469. PubMed ID: 25432788
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.
Meador CB; Jin H; de Stanchina E; Nebhan CA; Pirazzoli V; Wang L; Lu P; Vuong H; Hutchinson KE; Jia P; Chen X; Eisenberg R; Ladanyi M; Politi K; Zhao Z; Lovly CM; Cross DA; Pao W
Mol Cancer Ther; 2015 Feb; 14(2):542-52. PubMed ID: 25477325
[TBL] [Abstract][Full Text] [Related]
20. Endothelial growth factor receptor inhibitors in recurrent metastatic cancer of the head and neck.
Misiukiewicz K; Dang RP; Parides M; Camille N; Uczkowski H; Sarlis NJ; Posner M
Head Neck; 2016 Apr; 38 Suppl 1():E2221-8. PubMed ID: 25900280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
